arGEN-X BV (NASDAQ: ARGX) is one of 92 public companies in the “Biological products, except diagnostic” industry, but how does it compare to its competitors? We will compare arGEN-X BV to similar companies based on the strength of its dividends, risk, earnings, valuation, profitability, analyst recommendations and institutional ownership.
Insider and Institutional Ownership
52.8% of arGEN-X BV shares are held by institutional investors. Comparatively, 48.7% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 17.1% of shares of all “Biological products, except diagnostic” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
This table compares arGEN-X BV and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|arGEN-X BV Competitors||-6,095.52%||-68.88%||-26.12%|
Earnings and Valuation
This table compares arGEN-X BV and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|arGEN-X BV||$44.74 million||-$31.73 million||-70.13|
|arGEN-X BV Competitors||$1.03 billion||$94.79 million||-1.79|
arGEN-X BV’s competitors have higher revenue and earnings than arGEN-X BV. arGEN-X BV is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This is a breakdown of recent ratings for arGEN-X BV and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|arGEN-X BV Competitors||509||1807||4712||170||2.63|
arGEN-X BV currently has a consensus target price of $108.50, suggesting a potential upside of 10.51%. As a group, “Biological products, except diagnostic” companies have a potential upside of 16.28%. Given arGEN-X BV’s competitors higher possible upside, analysts plainly believe arGEN-X BV has less favorable growth aspects than its competitors.
About arGEN-X BV
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It is also developing ARGX-111 to treat solid tumors; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia. The company has license and collaboration agreements with AbbVie S.Á.R.L.; Bird Rock Bio, Inc.; LEO Pharma A/S; Staten Biotechnology B.V.; and Shire International GmbH. argenx SE was founded in 2008 and is based in Breda, the Netherlands.
Receive News & Ratings for arGEN-X BV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for arGEN-X BV and related companies with MarketBeat.com's FREE daily email newsletter.